On November 2, 2024, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, Escugen's core product ESG401 (recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate) was granted Breakthrough Therapy Designation (BTD). 

On September 26, 2024, in Shanghai —— The final of the 2024 "Maker China" Shanghai SME Innovation and Entrepreneurship Competition was held at the Zhangjiang Science Hall.